Dr. Simon Khagi, MD
Claim this profileUNC Lineberger Comprehensive Cancer Center
Studies Brain Cancer
Studies Glioblastoma
7 reported clinical trials
14 drugs studied
Area of expertise
1Brain Cancer
Stage IV
IDH positive
Stage III
2Glioblastoma
Stage IV
IDH positive
Stage III
Affiliated Hospitals
Clinical Trials Simon Khagi, MD is currently running
Targeted Therapy
for Brain Cancer
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.
Recruiting1 award Phase 217 criteria
N-803 + PD-L1 t-haNK + Bevacizumab
for Glioblastoma
This is a phase 2 open-label study to evaluate the safety and efficacy of N-803 and PD-L1 t-haNK when combined with Bevacizumab in subjects with recurrent or progressive GBM. Participants will receive N-803 subcutaneously (SC), PD-L1 t-haNK intravenously (IV), and Bevacizumab IV combination therapy. Treatment for all enrolled participants will consist of repeated cycles of 28 days for a maximum treatment period of 76 weeks (19 cycles). Treatment will be administered on days 1 and day 15 of each cycle. Treatment will be discontinued if the participant reports unacceptable toxicity (not corrected with dose reduction), withdraws consent, if the Investigator feels it is no longer in the participant's best interest to continue treatment, or the participant has confirmed progressive disease by iRANO, unless the participant is potentially deriving benefit per Investigator's assessment. Participants will be followed for collection of survival status every 12 weeks (± 2 weeks) for the first 2 years, then yearly thereafter.
Recruiting1 award Phase 24 criteria
More about Simon Khagi, MD
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Simon Khagi, MD has experience with
- HKI-272
- NovoTTF-100M Device
- NovoTTF-200M Device
- N-803
- PD-L1 T-haNK
- Bevacizumab
Breakdown of trials Simon Khagi, MD has run
Glioblastoma
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Simon Khagi, MD specialize in?
Simon Khagi, MD focuses on Brain Cancer and Glioblastoma. In particular, much of their work with Brain Cancer has involved Stage IV patients, or patients who are IDH positive.
Is Simon Khagi, MD currently recruiting for clinical trials?
Yes, Simon Khagi, MD is currently recruiting for 2 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Simon Khagi, MD has studied deeply?
Yes, Simon Khagi, MD has studied treatments such as HKI-272, NovoTTF-100M device, NovoTTF-200M device.
What is the best way to schedule an appointment with Simon Khagi, MD?
Apply for one of the trials that Simon Khagi, MD is conducting.
What is the office address of Simon Khagi, MD?
The office of Simon Khagi, MD is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.